Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 59

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 59
---
.” Consideration to Be Received in the Business Combination Following the entry into Amendment No. 4 to the Merger Agreement (as defined above), the aggregate consideration to be received by the Profusa shareholders is based on the sum of (a) the pre -transactionequity value of $155,000,000, plus (b) the Incentive Equity Value (which is expected to be $29,018,330 for purposes of this proxy statement/prospectus), plus (c) the Private Placement Value (which is expected to be $14,867,899 for purposes of this proxy statement/prospectus), plus (d) the Aggregate Exercise Price, minus (e) the Aggregate Company Incentive Amount. In accordance with the terms and subject to the conditions of the Merger Agreement, immediately prior to the Effective Time, each issued and outstanding share of Profusa preferred stock, par value $0.01, shall be converted into a number of shares of Profusa common stock, par value $0.01 (“New Profusa Common Stock”). At the Effective Time of the Merger, (i) each issued and outstanding share of Profusa Common Stock shall be converted into a number of shares of New Profusa Common Stock, based on the Exchange Ratio described below, (ii) each option to purchase Profusa Common Stock shall be converted into an option to purchase New Profusa Common Stock at the Exchange Ratio, and (iii) each warrant to purchase Profusa Common Stock shall be converted into a warrant to purchase New Profusa Common Stock at the Warrant Ratio (as defined in the Merger Agreement). The Exchange Ratio will be equal to the value of a share of Profusa Common Stock, based on the sum of (a) an equity valuation of Profusa of $155,000,000 and (b) the Incentive Equity Value (which is expected to be $29,018,330 for purposes of this proxy statement/prospectus), plus (c) the Private Placement Value (which is expected to be $14,867,899 for purposes of this proxy statement/prospectus), plus (d) the Aggregate Exercise Price, minus (e) the Aggregate Company Incentive Amount, divided by an assumed value of New Profusa Common Stock of $10.00 per share. As of May8, 2025, the Exchange Ratio and the Company Reference Share Value are estimated to be 0.75 and $7.47, respectively, at the time of Closing. Subject to certain